Try our Advanced Search for more refined results
Life Sciences - November, 2014
244 articles
- Duane Morris Guides Sex Dysfunction Drug Co.'s Pared IPO
- PTAB Bars Inventor From Proceeding Pro Se In AIA Review
- Ackman Says Allergan Sale May Net $6B For Pershing Square
- 2 Years On, FCA Battles Test Caronia Ruling's Reach
- Medtronic Gets Conditional FTC Nod On $43B Inversion Deal
- Latham Leads November's IPO Action With Work On 8 Deals
- Novartis Sheds Nicotine Patches To Clear Way For Glaxo Deal
- Avandia Insurers Denied Class Cert. In Suit Against Glaxo
- Life Sciences MVP: White & Case's Dimitrios Drivas
- Judge Nixes False-Labeling Suit Over Merck Sunscreens
- 5 Lessons From DOJ's Blockbuster FCA Haul
- Fla. Stock Scheme Atty Sees Post-Trial Motions Rejected
- Pfizer On Sidelines As AstraZeneca Offer Window Opens
- Shire Backers Say AbbVie Execs Lied About Inversion Upside
- Amgen Likely To Be Leading Case Affecting ERISA Pleading
- What To Know About Extending Patent Term In Southeast Asia
- Deals Rumor Mill: BT Group, Bayer, Clarksons
- Market Rumors: GlaxoSmithKline, Keppel, Jasmine Broadband
- 3rd Circ. Won't Revive FCA Suit Against Siemens
- 2nd-Ever Post-Grant Review Ends In Settlement
- Novartis' Painkiller Pricing Strategy Deemed Legal
- Judge Nixes Spine Surgery Patents, Citing Nautilus
- Remembering Doar: Justice As A 4-Letter Word
- CR Bard Pelvic Mesh MDL Plaintiffs Want Suits Combined
- Ex-ArthroCare CEO Wants Retrial Over $756M Fraud Scheme
- Lundbeck CEO Resigns In Ethics Breach Over Outside Shares
- Texas Court Won't Make Zimmer Retry Metal Plate Suit
- Coke, GSK Must Help Clean Up Ohio Site, Supreme Court Told
- Deals Rumor Mill: Glencore, Actavis, Stryker
- Abbott Settles $3.4M Pension Row With Trucking Co.
- Don't Review Invalidation Of Apotex Patent, Fed. Circ. Told
- AstraZeneca Can't End Nexium Pay-For-Delay Trial
- FDA Warns Of Cancer Risk With Uterine Fibroid Surgery Tool
- J&J Unit's Junk Faxes Are Ads, Not Info, Plaintiffs Say
- USTR Stumps For Better IP Protection Ahead Of India Summit
- 'Tis The Season … For Data Breaches And Data Analytics
- Calif. Court Takes On Jurisdiction Dispute In Plavix Suit
- 11th Circ. Asked To Revive Fraud Claims Over Chinese Pharma
- NuScience Atty Tests Judge's Patience At IP Sanctions Hearing
- Nexium Pay-For-Delay Plaintiffs Can't Prove Conspiracy
- Device Cos. Want Separate Twitter Guidance From FDA
- Supplement Co. Nutronics Can't Dodge False-Ad Class Action
- 3rd Circ. Urged To Revive FCA Suit Over Wholesale Drug Costs
- Differentiate Your Litigation Practice With Data Security
- Eli Lilly, Takeda Win Dismissal Of Ark. Taxpayer Actos Suit
- Solace For Wis. Suppliers Over Defective Components
- Is Stockpiling Protected By Hatch-Waxman Safe Harbor?
- Fed Circ. Threatens Sanctions For Redacted Legal Args
- Aeterna Faces Shareholder Suit Over Growth Hormone Drug
- USPTO Official Says New Eligibility Rules Will Quell Fears
- Allergan Hit With $6.5M Verdict In Off-Label Botox Suit
- Roche Wins Ruling At Fed. Circ. On Provitamin Imports
- Judge Scolds Kirkland & Ellis Attys In Ranbaxy-FDA Row
- AstraZeneca Seeks Judgment In Nexium Pay-For-Delay Case
- Genentech Must Pony Up $3M In Mass. Excise Tax
- Valeant Unveils $2B Buyback Plan After Failed Allergan Deal
- Perrigo Plans $900M Offering To Raise Cash For Omega Buy
- $6B Record Haul For DOJ As FCA Reaches New Heights
- SEC Suspends Trading In 4 Stocks, Citing Ebola Fraud Fears
- Boston Scientific Slammed With $18.5M Verdict In Mesh Trial
- J&J, Guidant Trade Barbs In Trial Over Failed $21B Merger
- Sanctions Sought For IP Firm's 'Baseless' $42M Counterclaim
- 2 Assumptions Shape 3rd Circ. Reverse Payment Case
- Novartis FCA Case Reaffirms Importance Of Company Policies
- The Print Room: How To Spend Less And Get More
- Ex-Pfizer Workers Lose Benefits Bid In Suit Over Wyeth Deal
- NIH Seeks Clinical Trial Data For Unapproved Products
- 7th Circ. Slams 'Selfish' $6.5M Deal In Supplement Suit
- Par Pharma Says Its New Drug Won't Rip Off GSK's Lamictal
- Ariosa Gets Stanford DNA Test Patent Nixed In AIA Review
- 3rd Circ. Told Actavis Allows Noncash Settlement Scrutiny
- CR Bard Can't Duck Its Part Of $5.5M Pelvic Mesh Verdict
- Ranbaxy Seeks Mistrial In Nexium Pay-For-Delay Case
- Novartis Can't Send Blood Pressure Suits Home
- Allergan Deal Clouds Rightful Activist Role In Hostile M&A
- DOJ Tallies $25B In Fiscal 2014
- Cancer Biotech Co. Bellicum Pharma Files For $115M IPO
- Royalty Pharma Pays $3.3B For Cystic Fibrosis Drug Royalties
- Law360 MVP Awards Go To Legal Aces From 78 Firms
- Lawyers Tell 8th Circ. To Uphold Jones Day Atty Sanctions
- Novo Nordisk Pays $19M To Settle Prandin Antitrust Action
- AstraZeneca Touts Drug Pipeline Amid Pfizer Bid Speculation
- LifeNet Wins $35M Verdict In Tissue Graft Patent Suit
- French Biotech Files For $100M US IPO To Boost R&D
- 2014 M&A Clears $3T Mark After Allergan, Halliburton Deals
- Reed Smith Atty's Widow Pushes For GSK Docs In Paxil Fight
- En Banc 9th Circ. Reverses Remand Of Teva Painkiller Suits
- CORRECTED: Pharmas Can't Nix Lidoderm MDL Over $170M Pay-For-Delay Deals
- FDA Pushes Back Rule On Generic-Drug Warning Labels
- Fed. Circ. Affirms Warner Chilcott's Actonel Patents Invalid
- Market Rumors: Johnson & Johnson, Roots Group, Alibaba
- Novartis Fights Zometa Jaw Injury Verdict In 11th Circ.
- 5 Ways To Boost An IPO For A No-Profit, Low-Revenue Issuer
- Lab Group Taps Paul Clement, Laurence Tribe For FDA Battle
- Abbott Labs Wants Trucking Co. Atty DQ'd In Contract Row
- GSK Tells 3rd Circ. Avandia RICO Claims Don't Hold Up
- Medtronic Confirms $42.9B Covidien Inversion On Track
- Zoetis Launches $500M Share Buyback As Activists Circle
- Actavis Reveals Allergan Breakup Fee, Board Picks
- Dewey Partner Clawback Ruling May Hurt New York Law Firms
- Pushback Prompts FDA To Propose New Food Safety Rules
- W.Va. Jury Finds Takeda Destroyed Key Actos Documents
- Citing Soul Hit, 11th Circ. Affirms $1.3M Axiom TM Win
- ALJ Stubs Out Fla. Lottery Plan For Medical Pot Dispensers
- Original-Patent Rule Dooms Drug Injection Complaint
- 5 Must-Know Facts About Allergan's $66B Actavis Tie-Up
- 3rd Circ. To Decide If Reverse Payments Must Be Cash
- Hearing Aid Maker Sonova Launches $518M Share Buyback
- Ranbaxy Sues FDA Over Nixed Approvals Of Generics
- Pfizer, Merck Reach $2.9B Deal To Develop Cancer Drug
- Biopharma Co. Juno Seeks IPO To Expand Cancer Drug R&D
- Abbott Unloads Animal Health Biz In $255M Zoetis Deal
- Post-Grant Review May Impact Biosimilars Litigation
- Allergan Finds White Knight In $66B Actavis Takeover
- Kilpatrick Urges Toss Of Medication-Cart IP Theft Claims
- SEC Wants $602M SAC Settlement To Go To Victims
- Valeant Disclosures Approved In Allergan Inside Trading Row
- Drug Return Co., Execs Plead Not Guilty To $116M Fraud
- 4 Things To Know As Feds Ditch 340B 'Mega Rule'
- Pharma Exec Can't Duck SEC's Pump-And-Dump Suit
- Biomerieux Sinks Lab's Suit Over Faulty Testing System
- Pliva Asks High Court To Review Generic Drug Ruling
- Market Rumors: Medtronic, Pemex, Beijing Infrastructure
- Philips Wants To Drain $467M Blood Sensor IP Verdict
- Deals Rumor Mill: Hostess, Azadea, Pfizer
- Vascular Solutions, CEO Indicted For Unapproved Sales
- Whole Foods Tries To 'Pick Off' Homeopathy Class Action
- Minority Powerbrokers Q&A: Weil's Laura Wilkinson
- Biotech Co. FibroGen Raises $146M In Upper Range IPO
- ITC Trends Medical Device Companies Should Know About
- Boston Scientific Hit With $27M Bellwether Mesh Verdict
- Ethicon Gets 76 Pelvic Mesh Users' Claims Nixed In Texas
- Liberty Medical Wins Approval For $68.5M Bankruptcy Sale
- Abbott Wants HIV-Drug Fight With GSK Narrowed For Retrial
- 5 Reasons Israeli Cos. Are Flirting With US Markets
- Allergan Slams Proposed Disclosures In Insider Trading Suit
- Dr. Reddy's Denied Quick Win In Consultant Noncompete Row
- Class Certified In GNC Wage Statement Suit
- Jury Clears J&J Unit In Children's Tylenol Suit
- Questcor Securities Class Clinches Certification
- Derivative Suit Faults Allergan Board For Rejecting Valeant Bid
- PRA Health Sciences Raises $305M After IPO Misses Mark
- CLOs: Fight Fraud With Better Analytics
- The Latest Life Sciences Company To Make FCPA Headlines
- Bankrupt Dendreon Eyes Possible Auction In February
- Allergan Wants Miotox Patent Invalidated In $600M Botox Row
- Panel To Probe Dickstein Shapiro's Wooing Of AG
- Medtronic Offers EU Concessions On $43B Covidien Bid
- Reglan Failure-To-Warn Claims Not Preempted, NJ Court Says
- DOJ's Investigation Into Generic Pharma Pricing Is Unusual
- Braintree Asks High Court To Hear Claim Construction Row
- Don't Read Too Much Into AbbVie Case, FTC's Feinstein Says
- DaVita Hit With Sanction Request In Kidney Drug FCA Suit
- Bankrupt Natrol Gets Nod For $132.5M Sale To Aurobindo
- Allergan Amends Bylaws Ahead Of Potential Proxy Fight
- Context Is Key For Sunshine Payments Under ACA
- Becton Must Pony Up $340M In Syringe Antitrust Suit
- Aurobindo Blows Away Natrol Stalking Horse With $132M Bid
- Chicago Hits Back At Drugmakers' Cohen Milstein DQ Bid
- Attys' Fee Award Cut To $91M In Pfizer Neurontin MDL
- Deals Rumor Mill: Solvay, Time Warner, Too Faced Cosmetics
- Drug Cos. Seek Judgment In Nexium Pay-For-Delay Case
- King & Spalding Adds Ex-FDA Medical Device Ace In DC
- Cancer Drug Maker Dendreon Hits Ch. 11 Hoping To Sell
- Japanese Medical Device Rules Stress Speed, Uniformity
- Del. Court Is 1st To Apply Daimler To Hatch-Waxman Case
- Lilly Defeats Cymbalta Label Suit As Possible MDL Looms
- Class Wins Partial Cert. In Flu Remedy Labeling Suit
- 9th Circ. Delivers Partial Win For Baby Gender Prediction Co.
- Taxation With Representation: Cravath, Vinson, Cooley
- Allergan Shareholder Claims Not Ripe, Chancery Rules
- Biotronik Pays $4.9M To Settle FCA Kickback Claims
- Weil Reps Advent, Avista In $1.5B Spinout Of UCB Pharma Co.
- Probiotic False Ad Class Action Against Bayer Survives
- Clinical Development Co. INC Research Raises $150M In IPO
- Ackman Says Valeant Can Pay Max Bid For Allergan
- FDA Accused Of Failing To Fully Vet Animal Growth Drugs
- Allergan Decision May Chill Bidder-Activist Partnerships
- $1B Stryker Deal Shows Path To Trial-Free MDL Settlements
- Nature Made Supplement Buyers Near Cert. In False Ad Suit
- FDA Yanks Ranbaxy's Approvals For Generic Nexium, Valcyte
- Cephalon Wants FCA Off-Label Suits Heard Separately
- 3rd Circ. Urged To Rethink Reviving Genaera Investor Suit
- SEC May Question Journalist In Onyx Insider Trading Probe
- Allergan Confirms Deal Talks With Potential New Suitor
- Calif. Med Tech Co. Nevro Raises $126M In Upsized IPO
- FDA Issues Warning To Sciecure Over Insomnia Drug Promo
- Applera Urges Fed. Circ. To Nix Enzo DNA Patent Win
- Market Rumors: Drybar, Bojangles, Walgreen
- Why Big-Ticket Deal Failures Don't Spell Trouble For M&A
- Enzymotec Investors Want Suits Over $70M IPO Combined
- Siemens Abandons Spinoff IPO For $2.7B Private Sale To EQT
- Perrigo Pays €3B For Bigger Slice Of Buzzing OTC Drug Space
- AstraZeneca CEO Says Inversion Rules Undercut Pfizer Bid
- 5 Ways To Uncover Bias During Jury Selection
- Secondary Considerations For Pharma Patents Get 2nd Look
- Broker Pleads Guilty After SEC BigLaw Tipster Case
- Endo, Teikoku Monopoly Claims Likely Out In Lidoderm MDL
- FDA Sued Over Detained Chinese Leg Braces
- 9 Votes On Health Ballot Measures You Might Have Missed
- ACA's Med Device Tax Causes Scant Harm, Report Says
- Robbins Arroyo Investigates Bio-Rad After $55M FCPA Deal
- Pfizer Nixes Pharmacists' Claims In Lipitor Pay-To-Delay Row
- Wash. Tax Board Rules Medical Weed Subject To Sales Tax
- A-Rod Admitted To Using Steroids, Bought Cousin's Silence
- How Senate Without Filibuster-Proof Majority Avoids Gridlock
- Walgreen Blood Tester Throws Down Gauntlet In Rival TM Row
- NLRB Judge Faults McKesson Over Plot To Decertify Union
- Nexium Buyers Seek Litigation Docs From AstraZeneca
- Confidential Witness Denies Testimony In Remoxy Suit
- FDA Asks Court To Stop Dietary Supplement Co. Sales
- In Allergan Insider Trade Ruling, Questions Upstage Answers
- Pfizer Says Plaintiffs In Zoloft MDL Can't Prove Causation
- Fresenius Brings Antibiotics Row With Cubist To PTAB
- Endocyte Investor Sues Over Faulty Drug In $1B Merck Deal
- Gene Therapy Co. Xenon Pharma Misses Target In $36M IPO
- Venture-Backed Glaucoma Co. Seeks To Raise $86.3M In IPO
- GOP Poised To Slow Down Obama Product Safety Measures
- GOP Senate Will Press FDA To Ease Up
- FDA Urged To Ban Drug Coating Chemical
- J&J Wins Dismissal Of Listerine False Labeling Suit
- High Court Likely Won't Affirm 6th Circ. Omnicare Ruling
- Royal DSM To Unload 3 Biz Units Amid Investor Pressure
- ICV Partners Presents $84M Offer For Bankrupt Natrol
- FDA Backs Tougher Warnings For Nexium, Prilosec
- Ackman Can Vote Allergan Shares Amid Insider Trading Flap
- Ex-Orioles Player Calls Insider Trading Charges 'Stale'
- Double Patenting: Old Tool For Generics And Biosimilars
- Stryker To Pay $1B To Settle Hip Implant MDL Claims
- Generic Drug Patent Cases On The Rise In 2014, Report Says
- Dentons Nabs Four Insurance Litigators From Riker Danzig
- Pa. Woman Says Shire Dumped Her For Whistleblowing
- CMS Axes Sunshine Act Exemption For Continuing Education
- Calls Grow For Fed. Circ. To Eye Laches Post-'Raging Bull'
- Expert In Pelvic Mesh MDL Shouldn't Be DQ'd, Plaintiffs Say
- 2 Biotechs Polish IPO Plans As Market Heats Back Up
- 3rd Circ. OKs FTC To Join Lamictal Oral Arguments
- Bio-Rad Pays $55M To Settle Feds' FCPA Investigations
- KKR-Backed Clinical Trials Co. Sets Terms For $400M IPO
- Allergan Says New Suitor Approached It About A Deal
- J&J Heir Wants Proskauer Documents In Tax Shelter Suit
- LabCorp Acquires Covance In $6.1B In Cash-Stock Deal
- Bristol-Myers V. Teva: What Doomed The Entecavir Patent
- Digesting The FDA's Changes To Animal Food Regulations